舒尼替尼的长期反应：依维莫司治疗转移性透明细胞肾细胞癌
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.
作者信息
Czarnecka Anna M, Sobczuk Paweł, Korniluk Jan, Spychalska Marta, Bogusz Krzysztof, Owczarek Anna, Brodziak Anna, Labochka Dominika, Moszczuk Barbara, Szczylik Cezary
机构信息
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
出版信息
Future Oncol. 2017 Jan;13(1):31-49. doi: 10.2217/fon-2016-0355. Epub 2016 Sep 6.
AIM
The study aim was to evaluate progression-free survival (PFS) and overall survival (OS) in patients with metastatic clear cell renal cell carcinoma on sunitinib (SU) and SU-everolimus treatment.
PATIENTS & METHODS: After 7 years of enrollment and 9 years of follow-up, 193 consecutively presenting patients (151 men and 42 women) were treated.
RESULTS
A total of 157 patients (81.3%) died and 36 patients (18.7%) survived. Median PFS in 193 SU-treated patients was 14.7 months and OS was 28.8 months. Median PFS was 13.98 months and median OS was 26.67 months in 175 patients treated with SU only or on SU-everolimus.
CONCLUSION
The development of SU-induced hypothyroidism, hypertension, neutropenia and edema was a significant predictive and prognostic factor.
目的
本研究旨在评估接受舒尼替尼（SU）和SU-依维莫司治疗的转移性透明细胞肾细胞癌患者的无进展生存期（PFS）和总生存期（OS）。
患者与方法
在入组7年和随访9年后，对193例连续就诊的患者（151例男性和42例女性）进行了治疗。
结果
共有157例患者（81.3%）死亡，36例患者（18.7%）存活。193例接受SU治疗的患者的中位PFS为14.7个月，OS为28.8个月。仅接受SU或接受SU-依维莫司治疗的175例患者的中位PFS为13.98个月，中位OS为26.67个月。
结论
SU引起的甲状腺功能减退、高血压、中性粒细胞减少和水肿的发生是一个重要的预测和预后因素。
Zotero 插件